Vous êtes sur la page 1sur 9

Generic

Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
Phenytoin
(diphenyl-
hydantoin)
Dilantin Tonic-
clonic
(grand
mal)
Focal-
onset
300
400
mg/d
(36
mg/kg,
adult;
48
mg/kg,
child);
qd-bid
24 h (wide
variation,
dose-
dependent)
1020
g/mL
Dizziness
Diplopia
Ataxia
Incoordinati
on
Confusion
Gum
hyperplasia
Lymphadenopa
thy
Hirsutism
Osteomalacia
Facial
coarsening
Skin rash
Level
increased by
isoniazid,
sulfonamide
s, fluoxetine
Level
decreased
by enzyme-
inducing
drugs
a

Altered
folate
metabolism
Carbamazepi
ne
Tegretol
Carbatr
ol
Tonic-
clonic
Focal-
600
1800
mg/d
(1535
1017 h 612 g/mL Ataxia
Dizziness
Diplopia
Aplastic anemia
Leukopenia
Gastrointestinal
Level
decreased
by enzyme-
inducing
Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
onset mg/kg,
child);
bid-qid
Vertigo irritation
Hepatotoxicity
Hyponatremia
drugs
a

Level
increased by
erythromyci
n,
propoxyphe
ne,
isoniazid,
cimetidine,
fluoxetine
Valproic acid Depake
ne
Depakot
e
Depakot
e ER
Tonic-
clonic
Absence
Atypical
absence
Myoclon
750
2000
mg/d
(2060
mg/kg)
; bid-
qid
15 h 50125
g/mL
Ataxia
Sedation
Tremor
Hepatotoxicity
Thrombocytope
nia
Gastrointestinal
irritation
Weight gain
Level
decreased
by enzyme-
inducing
drugs
a


Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
ic
Focal-
onset
Transient
alopecia
Hyperammone
mia
Lamotrigine Lamictal Focal-
onset
Tonic-
clonic
Atypical
absence
Myoclon
ic
Lennox-
Gastaut
syndro
150
500
mg/d;
bid
25 h
14 h (with
enzyme-
inducers)
59 h (with
valproic
acid)
Not
established
Dizziness
Diplopia
Sedation
Ataxia
Headache
Skin rash
Stevens-
Johnson
syndrome
Level
decreased
by enzyme-
inducing
drugs
a
and
oral
contraceptiv
es
Level
increased by
valproic acid
Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
me
Ethosuximid
e
Zarontin Absence
(petit
mal)
750
1250
mg/d
(20-40
mg/kg)
; qd-bid
60 h, adult
30 h, child
40100
g/mL
Ataxia
Lethargy
Headache
Gastrointestinal
irritation
Skin rash
Bone marrow
suppression

Gabapentin Neuront
in
Focal-
onset
900
2400
mg/d;
tid-qid
59 h Not
established
Sedation
Dizziness
Ataxia
Fatigue
Gastrointestinal
irritation
Weight gain
Edema
No known
significant
interactions
Topiramate Topama
x
Focal-
onset
Tonic-
200
400
mg/d;
2030 h Not
established
Psychomoto
r slowing
Sedation
Renal stones
(avoid use with
other carbonic
anhydrase
Level
decreased
by enzyme-
inducing
Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
clonic
Lennox-
Gastaut
syndro
me
bid Speech or
language
problems
Fatigue
Paresthesia
s
inhibitors)
Glaucoma
Weight loss
Hypohydrosis
drugs
a


Tiagabine Gabitril Focal-
onset
Tonic-
clonic
3256
mg/d;
bid-qid
79 h Not
established
Confusion
Sedation
Depression
Dizziness
Speech or
language
problems
Paresthesia
Gastrointestinal
irritation
Level
decreased
by enzyme-
inducing
drugs
a


Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
s
Psychosis
Phenobarbita
l
Luminol Tonic-
clonic
Focal-
onset
60180
mg/d
(14
mg/kg,
adult);
(36
mg/kg,
child);
qd
90 h (70 h
in children)
1040
g/mL
Sedation
Ataxia
Confusion
Dizziness
Decreased
libido
Depression
Skin rash Level
increased by
valproic
acid,
phenytoin
Primidone Mysolin
e
Tonic-
clonic
Focal-
onset
750
1000
mg/d
(1025
mg/kg)
Primidone,
815 h
Phenobarbit
al, 90 h
Primidone,
412 g/mL
Phenobarbit
al, 1040
Same as
phenobarbit
al

Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
; bid-tid g/mL
Clonazepam Klonopi
n
Absence
Atypical
absence
Myoclon
ic
112
mg/d
(0.1
0.2
mg/kg)
; qd-tid
2448 h 1070
ng/mL
Ataxia
Sedation
Lethargy
Anorexia Level
decreased
by enzyme-
inducing
drugs
a


Felbamate Felbatol Focal-
onset
Lennox-
Gastaut
syndro
me
2400
3600
mg/d,
(45
mg/kg,
child);
tid-qid
1622 h Not
established
Insomnia
Dizziness
Sedation
Headache
Aplastic anemia
Hepatic failure
Weight loss
Gastrointestinal
irritation
Increases
phenytoin,
valproic
acid, active
carbamazepi
ne
metabolite
Levetiraceta
m
Keppra Focal-
onset
1000
3000
mg/d;
68 h Not
established
Sedation
Fatigue
Anemia
Leukopenia
None known
Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
bid Incoordinati
on
Psychosis
Zonisamide Zonegra
n
Focal-
onset
200
400
mg/d;q
d-bid
5068 h Not
established
Sedation
Dizziness
Confusion
Headache
Psychosis
Anorexia
Renal stones
Hypohydrosis
Level
decreased
by enzyme-
inducing
drugs
a


Oxcarbazepi
ne
Trileptal Focal-
onset
900
2400
mg/d
(3045
mg/kg,
child);
1017 h
(for active
metabolite)
Not
established
Fatigue
Ataxia
Dizziness
Diplopia
See
carbamazepine
Level
decreased
by enzyme-
inducing
drugs
a

May
Generic
Name
Trade
Name
Princip
al Uses
Typical
Dose;
Dose
Interv
al
Half-Life Therapeuti
c Range
Neurologic Systemic Drug
Interaction
s
bid Vertigo
Headache
increase
phenytoin

Vous aimerez peut-être aussi